Regenxbio Inc
Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
18.945
0.115
(0.611%)
Volume:
793,828
52 week range:
18.65 - 35.73
Market Cap:
823.419M
Company Description:
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.